Luminescent silica- based nanomaterials for biomedicine

Autores
Campelo, Adrián Esteban; Ortega, Claudia Alicia; Oppezzo, Pablo; Agotegaray, Mariela Alejandra
Año de publicación
2019
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Silicon dioxide (SiO2), a material known as “silica” presents properties that make it a good candidate as a biomaterial: it has a very labile surface for functionalization, it is easy to synthesize and it is biocompatible. Calcination after synthesis of silica NPs yields luminescent nanomaterials. Fluorescent NPs themselves would offer enhanced functionality in terms of these properties with respect to conventional organic fluorophores. In this work, the influence of the synthesis method on the hydrodynamic diameter of silica fluorescent NPs was studied in order to obtain an optimal formulation as potential theranostic. Stöber process, involving tetraethylorthosilicate (TEOS) and 3-aminopropyltriethoxysilane (APTES), has been applied to obtain different formulations from increasing APTES initial concentration. After synthesis, the NPs were calcined at 450 °C. Characterization was performed by FTIR, TEM, DRX, fluorescence spectroscopy/microscopy and DLS to determine hydrodynamic diameter (Hd). NPs synthesized without APTES do not present fluorescent properties, while the APTES containing NPs are fluorescent. Increasing concentration of APTES induces larger NPs with low stability in physiological medium. The optimal synthesis condition resulted with a TEOS:APTES ratio of 1:0.1 rendering a Hd of 450 nm with polydispersion index near 0.20. This formulation is suitable for biomedical applications in terms of Hd and stability as potential theranostic agent for multiple pathologies, including Chronic Lymphocytic Leukemia that is of our particular interest. CLL is the most common adult leukemia in Western countries and is defined by the accumulation of mature, CD5+ B lymphocytes in peripheral blood, bone marrow and secondary lymphoid organs. Despite important progress in treatment, relapse occurs and this leukemia remains incurable in many cases. New therapeutic approaches by innovative tools acting in synergism with the last therapies approved in CLL are desirable.
Fil: Campelo, Adrián Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; Argentina
Fil: Ortega, Claudia Alicia. Instituto Pasteur de Montevideo; Uruguay
Fil: Oppezzo, Pablo. Instituto Pasteur de Montevideo; Uruguay
Fil: Agotegaray, Mariela Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur; Argentina
LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas; VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio
Mar del Plata
Argentina
Sociedad Argentina de Investigación Clínica
Asociación Argentina de Farmacología Experimental
Sociedad Argentina de Biología
Sociedad Argentina de Protozoología
Asociación Argentina de Nanomedicinas
Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio
Materia
SILICA
NANOPARTICLES
CHRONIC LYMPHOCYTIC LEUKEMIA
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/221502
Acceder
id CONICETDig_db7639e975f454191990de2759a64b11
oai_identifier_str oai:ri.conicet.gov.ar:11336/221502
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Luminescent silica- based nanomaterials for biomedicineCampelo, Adrián EstebanOrtega, Claudia AliciaOppezzo, PabloAgotegaray, Mariela AlejandraSILICANANOPARTICLESCHRONIC LYMPHOCYTIC LEUKEMIAhttps://purl.org/becyt/ford/2.10https://purl.org/becyt/ford/2Silicon dioxide (SiO2), a material known as “silica” presents properties that make it a good candidate as a biomaterial: it has a very labile surface for functionalization, it is easy to synthesize and it is biocompatible. Calcination after synthesis of silica NPs yields luminescent nanomaterials. Fluorescent NPs themselves would offer enhanced functionality in terms of these properties with respect to conventional organic fluorophores. In this work, the influence of the synthesis method on the hydrodynamic diameter of silica fluorescent NPs was studied in order to obtain an optimal formulation as potential theranostic. Stöber process, involving tetraethylorthosilicate (TEOS) and 3-aminopropyltriethoxysilane (APTES), has been applied to obtain different formulations from increasing APTES initial concentration. After synthesis, the NPs were calcined at 450 °C. Characterization was performed by FTIR, TEM, DRX, fluorescence spectroscopy/microscopy and DLS to determine hydrodynamic diameter (Hd). NPs synthesized without APTES do not present fluorescent properties, while the APTES containing NPs are fluorescent. Increasing concentration of APTES induces larger NPs with low stability in physiological medium. The optimal synthesis condition resulted with a TEOS:APTES ratio of 1:0.1 rendering a Hd of 450 nm with polydispersion index near 0.20. This formulation is suitable for biomedical applications in terms of Hd and stability as potential theranostic agent for multiple pathologies, including Chronic Lymphocytic Leukemia that is of our particular interest. CLL is the most common adult leukemia in Western countries and is defined by the accumulation of mature, CD5+ B lymphocytes in peripheral blood, bone marrow and secondary lymphoid organs. Despite important progress in treatment, relapse occurs and this leukemia remains incurable in many cases. New therapeutic approaches by innovative tools acting in synergism with the last therapies approved in CLL are desirable.Fil: Campelo, Adrián Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; ArgentinaFil: Ortega, Claudia Alicia. Instituto Pasteur de Montevideo; UruguayFil: Oppezzo, Pablo. Instituto Pasteur de Montevideo; UruguayFil: Agotegaray, Mariela Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur; ArgentinaLXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas; VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de LaboratorioMar del PlataArgentinaSociedad Argentina de Investigación ClínicaAsociación Argentina de Farmacología ExperimentalSociedad Argentina de BiologíaSociedad Argentina de ProtozoologíaAsociación Argentina de NanomedicinasAsociación Argentina de Ciencia y Tecnología de Animales de LaboratorioFundación Revista Medicina2019info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/221502Luminescent silica- based nanomaterials for biomedicine; LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas; VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio; Mar del Plata; Argentina; 2019; 281-2820025-76801669-9106CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://medicinabuenosaires.com/revistas/vol79-19/s4/vol79_s4.pdfNacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T12:59:43Zoai:ri.conicet.gov.ar:11336/221502instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 12:59:43.378CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Luminescent silica- based nanomaterials for biomedicine
title Luminescent silica- based nanomaterials for biomedicine
spellingShingle Luminescent silica- based nanomaterials for biomedicine
Campelo, Adrián Esteban
SILICA
NANOPARTICLES
CHRONIC LYMPHOCYTIC LEUKEMIA
title_short Luminescent silica- based nanomaterials for biomedicine
title_full Luminescent silica- based nanomaterials for biomedicine
title_fullStr Luminescent silica- based nanomaterials for biomedicine
title_full_unstemmed Luminescent silica- based nanomaterials for biomedicine
title_sort Luminescent silica- based nanomaterials for biomedicine
dc.creator.none.fl_str_mv Campelo, Adrián Esteban
Ortega, Claudia Alicia
Oppezzo, Pablo
Agotegaray, Mariela Alejandra
author Campelo, Adrián Esteban
author_facet Campelo, Adrián Esteban
Ortega, Claudia Alicia
Oppezzo, Pablo
Agotegaray, Mariela Alejandra
author_role author
author2 Ortega, Claudia Alicia
Oppezzo, Pablo
Agotegaray, Mariela Alejandra
author2_role author
author
author
dc.subject.none.fl_str_mv SILICA
NANOPARTICLES
CHRONIC LYMPHOCYTIC LEUKEMIA
topic SILICA
NANOPARTICLES
CHRONIC LYMPHOCYTIC LEUKEMIA
purl_subject.fl_str_mv https://purl.org/becyt/ford/2.10
https://purl.org/becyt/ford/2
dc.description.none.fl_txt_mv Silicon dioxide (SiO2), a material known as “silica” presents properties that make it a good candidate as a biomaterial: it has a very labile surface for functionalization, it is easy to synthesize and it is biocompatible. Calcination after synthesis of silica NPs yields luminescent nanomaterials. Fluorescent NPs themselves would offer enhanced functionality in terms of these properties with respect to conventional organic fluorophores. In this work, the influence of the synthesis method on the hydrodynamic diameter of silica fluorescent NPs was studied in order to obtain an optimal formulation as potential theranostic. Stöber process, involving tetraethylorthosilicate (TEOS) and 3-aminopropyltriethoxysilane (APTES), has been applied to obtain different formulations from increasing APTES initial concentration. After synthesis, the NPs were calcined at 450 °C. Characterization was performed by FTIR, TEM, DRX, fluorescence spectroscopy/microscopy and DLS to determine hydrodynamic diameter (Hd). NPs synthesized without APTES do not present fluorescent properties, while the APTES containing NPs are fluorescent. Increasing concentration of APTES induces larger NPs with low stability in physiological medium. The optimal synthesis condition resulted with a TEOS:APTES ratio of 1:0.1 rendering a Hd of 450 nm with polydispersion index near 0.20. This formulation is suitable for biomedical applications in terms of Hd and stability as potential theranostic agent for multiple pathologies, including Chronic Lymphocytic Leukemia that is of our particular interest. CLL is the most common adult leukemia in Western countries and is defined by the accumulation of mature, CD5+ B lymphocytes in peripheral blood, bone marrow and secondary lymphoid organs. Despite important progress in treatment, relapse occurs and this leukemia remains incurable in many cases. New therapeutic approaches by innovative tools acting in synergism with the last therapies approved in CLL are desirable.
Fil: Campelo, Adrián Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Ciencias Biológicas y Biomédicas del Sur. Universidad Nacional del Sur. Departamento de Biología, Bioquímica y Farmacia. Instituto de Ciencias Biológicas y Biomédicas del Sur; Argentina
Fil: Ortega, Claudia Alicia. Instituto Pasteur de Montevideo; Uruguay
Fil: Oppezzo, Pablo. Instituto Pasteur de Montevideo; Uruguay
Fil: Agotegaray, Mariela Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Bahía Blanca. Instituto de Química del Sur. Universidad Nacional del Sur. Departamento de Química. Instituto de Química del Sur; Argentina
LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas; VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio
Mar del Plata
Argentina
Sociedad Argentina de Investigación Clínica
Asociación Argentina de Farmacología Experimental
Sociedad Argentina de Biología
Sociedad Argentina de Protozoología
Asociación Argentina de Nanomedicinas
Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio
description Silicon dioxide (SiO2), a material known as “silica” presents properties that make it a good candidate as a biomaterial: it has a very labile surface for functionalization, it is easy to synthesize and it is biocompatible. Calcination after synthesis of silica NPs yields luminescent nanomaterials. Fluorescent NPs themselves would offer enhanced functionality in terms of these properties with respect to conventional organic fluorophores. In this work, the influence of the synthesis method on the hydrodynamic diameter of silica fluorescent NPs was studied in order to obtain an optimal formulation as potential theranostic. Stöber process, involving tetraethylorthosilicate (TEOS) and 3-aminopropyltriethoxysilane (APTES), has been applied to obtain different formulations from increasing APTES initial concentration. After synthesis, the NPs were calcined at 450 °C. Characterization was performed by FTIR, TEM, DRX, fluorescence spectroscopy/microscopy and DLS to determine hydrodynamic diameter (Hd). NPs synthesized without APTES do not present fluorescent properties, while the APTES containing NPs are fluorescent. Increasing concentration of APTES induces larger NPs with low stability in physiological medium. The optimal synthesis condition resulted with a TEOS:APTES ratio of 1:0.1 rendering a Hd of 450 nm with polydispersion index near 0.20. This formulation is suitable for biomedical applications in terms of Hd and stability as potential theranostic agent for multiple pathologies, including Chronic Lymphocytic Leukemia that is of our particular interest. CLL is the most common adult leukemia in Western countries and is defined by the accumulation of mature, CD5+ B lymphocytes in peripheral blood, bone marrow and secondary lymphoid organs. Despite important progress in treatment, relapse occurs and this leukemia remains incurable in many cases. New therapeutic approaches by innovative tools acting in synergism with the last therapies approved in CLL are desirable.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Reunión
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/221502
Luminescent silica- based nanomaterials for biomedicine; LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas; VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio; Mar del Plata; Argentina; 2019; 281-282
0025-7680
1669-9106
CONICET Digital
CONICET
url http://hdl.handle.net/11336/221502
identifier_str_mv Luminescent silica- based nanomaterials for biomedicine; LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica; LI Reunión Anual de la Asociación Argentina de Farmacología Experimental; XXI Reunión Anual de la Sociedad Argentina de Biología; XXXI Reunión Anual de la Sociedad Argentina de Protozoología; IX Reunión Anual de la Asociación Argentina de Nanomedicinas; VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio; Mar del Plata; Argentina; 2019; 281-282
0025-7680
1669-9106
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://medicinabuenosaires.com/revistas/vol79-19/s4/vol79_s4.pdf
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.coverage.none.fl_str_mv Nacional
dc.publisher.none.fl_str_mv Fundación Revista Medicina
publisher.none.fl_str_mv Fundación Revista Medicina
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842979832794710016
score 13.004268

Publicaciones similares